The impact of continuous renal replacement therapy on antibiotic pharmacokinetics in critically ill patients

References

• Fleming GM. Renal replacement therapy review: past, present and future. Organogenesis. 2011 Jan-Mar;7(1):2–12.
   PubMed Web of Science ®Google Scholar
• Kumar A, Singh NP. Antimicrobial dosing in critically ill patients with sepsis-induced acute kidney injury. Indian J Crit Care Med. 2015 Feb;19(2):99–108.
   PubMed Web of Science ®Google Scholar
• Legrand M, Darmon M, Joannidis M, et al. Management of renal replacement therapy in ICU patients: an international survey. Intensive Care Med. 2013 Jan;39(1):101–108. .
   PubMed Web of Science ®Google Scholar
• Villa G, Neri M, Bellomo R, et al. Nomenclature for renal replacement therapy and blood purification techniques in critically ill patients: practical applications. Crit Care. 2016 Oct 10;20(1):283.
   PubMedGoogle Scholar
• Kitchlu A, Adhikari N, Burns KE, et al. Outcomes of sustained low efficiency dialysis versus continuous renal replacement therapy in critically ill adults with acute kidney injury: a cohort study. BMC Nephrol. 2015 Aug;4(16):127. .
   Google Scholar
• Jamal JA, Mueller BA, Choi GY, et al. How can we ensure effective antibiotic dosing in critically ill patients receiving different types of renal replacement therapy? Diagn Microbiol Infect Dis. 2015 May;82(1):92–103. .
   PubMed Web of Science ®Google Scholar
• Jamal JA, Udy AA, Lipman J, et al. The impact of variation in renal replacement therapy settings on piperacillin, meropenem, and vancomycin drug clearance in the critically ill: an analysis of published literature and dosing regimens. Crit Care Med. 2014 Jul;42(7):1640–1650.
   PubMed Web of Science ®Google Scholar
• O’Reilly P, Tolwani A. Renal replacement therapy III: IHD, CRRT, SLED. Crit Care Clin. 2005 Apr;21(2):367–378.
   PubMed Web of Science ®Google Scholar
• Deepa C, Muralidhar K. Renal replacement therapy in ICU. J Anaesthesiol Clin Pharmacol. 2012 Jul;28(3):386–396.
   PubMedGoogle Scholar
• Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016 Feb 23;315(8):801–810.
   PubMed Web of Science ®Google Scholar
• Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006 Jun;34(6):1589–1596. .
   PubMed Web of Science ®Google Scholar
• Roberts JA, De Waele JJ, Dimopoulos G, et al. DALI: defining Antibiotic levels in intensive care unit patients: a multi-centre point of prevalence study to determine whether contemporary antibiotic dosing for critically ill patients is therapeutic. BMC Infect Dis. 2012 Jul ;6(12):152. .
   Google Scholar
• Roberts JA, Joynt G, Lee A, et al. The effect of renal replacement therapy and antibiotic dose on antibiotic concentrations in critically ill patients: data from the multinational SMARRT Study. Clin Infect Dis. 2020 Mar 9; DOI:10.1093/cid/ciaa224.
   Web of Science ®Google Scholar
• Sader HS, Farrell DJ, Flamm RK, et al. Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009-2011). Diagn Microbiol Infect Dis. 2014 Apr;78(4):443–448.
   PubMed Web of Science ®Google Scholar
• Feretzakis G, Loupelis E, Sakagianni A, et al. A 2-Year single-centre audit on Antibiotic Resistance of Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae Strains from an Intensive Care Unit and Other Wards in a General Public Hospital in Greece. Antibiotics (Basel). 2019 May 15;8(2):2.
   Web of Science ®Google Scholar
• De Waele JJ, Carrette S, Carlier M, et al. Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial. Intensive Care Med. 2014 Mar;40(3):380–387. .
   PubMed Web of Science ®Google Scholar
• Claus BO, Hoste EA, Colpaert K, et al. Augmented renal clearance is a common finding with worse clinical outcome in critically ill patients receiving antimicrobial therapy. J Crit Care. 2013 Oct;28(5):695–700. .
   PubMed Web of Science ®Google Scholar
• Roberts JA, Norris R, Paterson DL, et al. Therapeutic drug monitoring of antimicrobials. Br J Clin Pharmacol. Jan;73(1):27–36. .
   PubMed Web of Science ®Google Scholar
• Jacobs A, Taccone FS, Roberts JA, et al. β-Lactam Dosage Regimens in Septic Patients with Augmented Renal Clearance. Antimicrob Agents Chemother. 2018 Sep;62(9). DOI:10.1128/AAC.02534-17
   Web of Science ®Google Scholar
• Jung B, Mahul M, Breilh D, et al. Repeated Piperacillin-Tazobactam Plasma Concentration Measurements in Severely Obese Versus Nonobese Critically Ill Septic Patients and the Risk of Under- and Overdosing. Crit Care Med. 2017 May;45(5):e470–e478.
   PubMed Web of Science ®Google Scholar
• Carlier M, Carrette S, Stove V, et al. Does consistent piperacillin dosing result in consistent therapeutic concentrations in critically ill patients? A longitudinal study over an entire antibiotic course. Int J Antimicrob Agents. 2014 May;43(5):470–473.
   PubMed Web of Science ®Google Scholar
• Roberts JA, Abdul-Aziz MH, Lipman J, et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014 Jun;14(6):498–509.
   PubMed Web of Science ®Google Scholar
• Hites M, Dell’Anna AM, Scolletta S, et al. The challenges of multiple organ dysfunction syndrome and extra-corporeal circuits for drug delivery in critically ill patients. Adv Drug Deliv Rev. 2014 Nov;20(77):12–21. .
   Google Scholar
• Drusano GL. Antimicrobial pharmacodynamics: critical interactions of ‘bug and drug’. Nat Rev Microbiol. 2004 Apr;2(4):289–300.
   PubMed Web of Science ®Google Scholar
• Dhaese S, Heffernan A, Liu D, et al. Prolonged versus intermittent infusion of ß-lactam Antibiotics: a systematic review and meta-regression of bacterial killing in preclinical infections models. Clin Pharmacokinet. 2020 Oct;59(10):1237–1250.
   PubMed Web of Science ®Google Scholar
• Roberts DM, Liu X, Roberts JA, et al. A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics. Crit Care. 2015 Mar 13;19(1):84.
   PubMedGoogle Scholar
• Macedo E, Mehta RL. Continuous Dialysis Therapies: core Curriculum 2016. Am J Kidney Dis. 2016 Oct;68(4):645–657.
   PubMed Web of Science ®Google Scholar
• Ashley CM, Clare. Introduction to Renal Therapeutics.  Ann Pharmacother 2008; p. 127–136.
   Google Scholar
• Kuang D, Verbine A, Ronco C. Pharmacokinetics and antimicrobial dosing adjustment in critically ill patients during continuous renal replacement therapy. Clin Nephrol. 2007 May;67(5):267–284.
   PubMed Web of Science ®Google Scholar
• Tian Q, Gomersall CD, Ip M, et al. Adsorption of amikacin, a significant mechanism of elimination by hemofiltration. Antimicrob Agents Chemother. 2008 Mar;52(3):1009–1013.
   PubMed Web of Science ®Google Scholar
• Choi G, Gomersall CD, Lipman J, et al. The effect of adsorption, filter material and point of dilution on antibiotic elimination by haemofiltration an in vitro study of levofloxacin. Int J Antimicrob Agents. 2004 Nov;24(5):468–472.
   PubMed Web of Science ®Google Scholar
• Choi G, Gomersall CD, Tian Q, et al. Principles of antibacterial dosing in continuous renal replacement therapy. Crit Care Med. 2009 Jul;37(7):2268–2282.
   PubMed Web of Science ®Google Scholar
• Ulldemolins M, Roberts JA, Rello J, et al. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet. 2011 Feb;50(2):99–110.
   PubMed Web of Science ®Google Scholar
• Ulldemolins M, Soy D, Llaurado-Serra M, et al. Meropenem population pharmacokinetics in critically ill patients with septic shock and continuous renal replacement therapy: influence of residual diuresis on dose requirements. Antimicrob Agents Chemother. 2015 Sep;59(9):5520–5528.
   PubMed Web of Science ®Google Scholar
• Barrasa H, Soraluce A, Isla A, et al. Pharmacokinetics of linezolid in critically ill patients on continuous renal replacement therapy: influence of residual renal function on PK/PD target attainment. J Crit Care. 2019 Apr;50:69–76.
   PubMed Web of Science ®Google Scholar
• Endre ZH, Pickering JW. Acute kidney injury: cell cycle arrest biomarkers win race for AKI diagnosis. Nat Rev Nephrology. 2014 Dec;10(12):683–685.
   PubMed Web of Science ®Google Scholar
• Pickering JW, Frampton CM, Walker RJ, et al. Four hour creatinine clearance is better than plasma creatinine for monitoring renal function in critically ill patients. Crit Care. 2012;16(3):R107.
   PubMed Web of Science ®Google Scholar
• Agence française de sécurité sanitaire des produits de santé. Update on good use of injectable aminoglycosides, gentamycin, tobramycin, netilmycin, amikacin. Pharmacological properties, indications, dosage, and mode of administration, treatment monitoring. Med Mal Infect. 2012;42(7):301–308.
   Google Scholar
• Bennett J, Dolin R, Blaser MJ. Principles and Practice of Infectious Diseases. 8th Edition (2014). Ed: Saunders.
   Google Scholar
• Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis. 1987 Jan;155(1):93–99.
   PubMed Web of Science ®Google Scholar
• Deziel-Evans LM, Murphy JE, Job ML. Correlation of pharmacokinetic indices with therapeutic outcome in patients receiving aminoglycosides. Clin Pharm. 1986 Apr;5(4):319–324.
   PubMedGoogle Scholar
• Marsot A, Guilhaumou R, Riff C, et al. Amikacin in Critically Ill Patients: a Review of Population Pharmacokinetic Studies. Clin Pharmacokinet. 2017 Feb;56(2):127–138.
   PubMed Web of Science ®Google Scholar
• Roger C, Wallis SC, Muller L, et al. Influence of Renal Replacement Modalities on Amikacin Population Pharmacokinetics in Critically Ill Patients on Continuous Renal Replacement Therapy. Antimicrob Agents Chemother. 2016 Aug;60(8):4901–4909.
   PubMed Web of Science ®Google Scholar
• Drusano GL, Louie A. Optimization of aminoglycoside therapy. Antimicrob Agents Chemother. 2011 Jun;55(6):2528–2531.
   PubMed Web of Science ®Google Scholar
• Brasseur A, Hites M, Roisin S, et al. A high-dose aminoglycoside regimen combined with renal replacement therapy for the treatment of MDR pathogens: a proof-of-concept study. J Antimicrob Chemother. 2016 May;71(5):1386–1394.
   PubMed Web of Science ®Google Scholar
• Bacopoulou F, Markantonis SL, Pavlou E, et al. A study of once-daily amikacin with low peak target concentrations in intensive care unit patients: pharmacokinetics and associated outcomes. J Crit Care. 2003 Jun;18(2):107–113.
   PubMed Web of Science ®Google Scholar
• Botha FJ, Van Der Bijl P, Seifart HI, et al. Fluctuation of the volume of distribution of amikacin and its effect on once-daily dosage and clearance in a seriously ill patient. Intensive Care Med. 1996 May;22(5):443–446.
   PubMed Web of Science ®Google Scholar
• Abdul-Aziz MH, Alffenaar JC, Bassetti M, et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper. Intensive Care Med. 2020 Jun;46(6):1127–1153.
   PubMed Web of Science ®Google Scholar
• Taccone FS, De Backer D, Laterre PF, et al. Pharmacokinetics of a loading dose of amikacin in septic patients undergoing continuous renal replacement therapy. Int J Antimicrob Agents. 2011 Jun;37(6):531–535. .
   PubMed Web of Science ®Google Scholar
• Ulldemolins M, Roberts JA, Wallis SC, et al. Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacikinetics. JAC. 2010 Aug;65(8):1771–1778.
   Google Scholar
• Schleibinger M, Steinbach CL, Töpper C, et al. Protein binding characteristics and pharmacokinetics of ceftriaxone in intensive care unit patients. Br J Clin Pharmacol. 2015 Mar;80(3):525–533.
   PubMed Web of Science ®Google Scholar
• Delattre IK, Taccone FS, Jacobs F, et al. Optimizing β-lactams treatment in critically-ill patients using pharmacokinetics/pharmacodynamics targets: are first conventional doses effective? Expert Rev Anti Infect Ther. 2017 Jul;15(7):677–688.
   PubMed Web of Science ®Google Scholar
• Taccone FS, Laterre PF, Dugernier T, et al. Insufficient beta-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care. 2010;14(4):R126.
   PubMed Web of Science ®Google Scholar
• Seyler L, Cotton F, Taccone FS, et al. Recommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy. Crit Care. 2011;15(3):R137.
   PubMed Web of Science ®Google Scholar
• Crass RL, Rodvold KA, Mueller BA, et al. Renal Dosing of Antibiotics: are We Jumping the Gun? Clin Infect Dis. 2019 Apr 24;68(9):1596–1602.
   PubMed Web of Science ®Google Scholar
• Roberts DM, Roberts JA, Roberts MS, et al. Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study. Crit Care Med. 2012 May;40(5):1523–1528.
   PubMed Web of Science ®Google Scholar
• Valtonen M, Tiula E, Backman JT, et al. Elimination of meropenem during continuous veno-venous haemofiltration and haemodiafiltration in patients with acute renal failure. J Antimicrob Chemother. 2000 May;45(5):701–704. .
   PubMed Web of Science ®Google Scholar
• Valtonen M, Tiula E, Takkunen O, et al. Elimination of the piperacillin/tazobactam combination during continuous venovenous haemofiltration and haemodiafiltration in patients with acute renal failure. J Antimicrob Chemother. 2001 Dec;48(6):881–885.
   PubMed Web of Science ®Google Scholar
• Zelenitsky S, Rubinstein E, Ariano R, et al. Vancomycin pharmacodynamics and survival in patients with methicillin-resistant Staphylococcus aureus-associated septic shock. Int J Antimicrob Agents. 2013 Mar;41(3):255–260. .
   PubMed Web of Science ®Google Scholar
• Wong G, Taccone F, Villois P, et al. β-Lactam pharmacodynamics in Gram-negative bloodstream infections in the critically ill. J Antimicrob Chemother. 2020 Feb 1;75(2):429–433.
   PubMed Web of Science ®Google Scholar
• Quinton MC, Bodeau S, Kontar L, et al. Neurotoxic Concentration of Piperacillin during Continuous Infusion in Critically Ill Patients. Antimicrob Agents Chemother. 2017 Sep;61(9). doi:10.1128/AAC.00654-17.
   PubMed Web of Science ®Google Scholar
• Imani S, Buscher H, Marriott D, et al. Too much of a good thing: a retrospective study of β-lactam concentration-toxicity relationships. J Antimicrob Chemother. 2017 Oct 1;72(10):2891–2897.
   PubMed Web of Science ®Google Scholar
• Lau C, Marriott D, Gould M, et al. A retrospective study to determine the cefepime-induced neurotoxicity threshold in hospitalized patients. J Antimicrob Chemother. 2020 Mar 1;75(3):718–725.
   PubMed Web of Science ®Google Scholar
• Beumier M, Casu GS, Hites M, et al. Elevated β-lactam concentrations associated with neurological deterioration in ICU septic patients. Minerva Anestesiol. 2015 May;81(5):497–506.
   PubMed Web of Science ®Google Scholar
• Soukup P, Faust AC, Edpuganti V, et al. Steady-state Ceftazidime-Avibactam serum concentrations and dosing recommendations in a critically ill patient being treated for Pseudomonas aeruginosa Pneumonia and undergoing continuous venovenous hemodiafiltration. Pharmacotherapy. 2019;39(12):1216–1222.
   PubMed Web of Science ®Google Scholar
• Wenzler E, Bunnell KL, Bleasdale SC, et al. Pharmacokinetics and dialtic clearance of ceftazidime-avibactam in a critically ill patient on continuous venovenous hemofiltration. Antimicrob Agents Chemother. 2017;61(7):e00464–17.
   PubMed Web of Science ®Google Scholar
• Sime FB, Lassig-Smith M, Starr T, et al. Population Pharmacokinetics of Unbound Ceftolozane and Tazobactam in Critically Ill Patients without Renal Dysfunction. Antimicrob Agents Chemother. 2019;63(10):e01265–19.
   PubMed Web of Science ®Google Scholar
• Sime FB, Lassig-Smith M, Starr T, et al. A population Pharmacokinetic Model-Guided Evaluation of Ceftolozane-Tazobactam Dosing in Critically Ill Patients Undergoing Continuous Venovenous Hemodiafiltration. Antimicrob Agents Chemother. 2020;64(1):e01655–19.
   Web of Science ®Google Scholar
• Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis. 2006 Jan 1;42(Suppl 1):S35–9.
   PubMedGoogle Scholar
• Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med. 2009 Mar;37(3):840–851. . quiz 859.
   PubMed Web of Science ®Google Scholar
• Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009 Jan 1;66(1):82–98.
   PubMedGoogle Scholar
• Rodvold KA, Blum RA, Fischer JH, et al. Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother. 1988 Jun;32(6):848–852.
   PubMed Web of Science ®Google Scholar
• Golper TA, Noonan HM, Elzinga L, et al. Vancomycin pharmacokinetics, renal handling, and nonrenal clearances in normal human subjects. Clin Pharmacol Ther. 1988 May;43(5):565–570.
   PubMed Web of Science ®Google Scholar
• Van De Vijsel LM, Walker SA, Walker SE, et al. Initial vancomycin dosing recommendations for critically ill patients undergoing continuous venovenous hemodialysis. Can J Hosp Pharm. 2010 May;63(3):196–206. .
   PubMedGoogle Scholar
• Del Mar Fernández De Gatta GM, Revilla N, Calvo MV, et al. Pharmacokinetic/pharmacodynamic analysis of vancomycin in ICU patients. Intensive Care Med. 2007 Feb;33(2):279–285.
   PubMed Web of Science ®Google Scholar
• DelDot ME, Lipman J, Tett SE. Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration. Br J Clin Pharmacol. 2004 Sep;58(3):259–268.
   PubMed Web of Science ®Google Scholar
• Santré C, Leroy O, Simon M, et al. Pharmacokinetics of vancomycin during continuous hemodiafiltration. Intensive Care Med. 1993;19(6):347–350.
   PubMed Web of Science ®Google Scholar
• James JK, Palmer SM, Levine DP, et al. Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections. Antimicrob Agents Chemother. 1996 Mar;40(3):696–700.
   PubMed Web of Science ®Google Scholar
• Wysocki M, Delatour F, Faurisson F, et al. Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother. 2001 Sep;45(9):2460–2467.
   PubMed Web of Science ®Google Scholar
• Yagasaki K, Gando S, Matsuda N, et al. PKs of teicoplanin in critically ill patients undergoing continuous hemodiafiltration. Intensive Care Med. 2003;29(11):2094–2095.
   PubMed Web of Science ®Google Scholar
• Ramos-Martin V, Johnson A, McEntee L, et al. Pharmacodynamics of teicoplanin against MRSA. JAC. 2017;72(12):3382–3389.
   Google Scholar
• Bellman R, Falkensammer G, Seger C, et al. Teicoplanin pharmacokinetics in critically ill patients on continuous veno-venous hemofiltration. Int J Clin Pharmacol Ther. 2010;48(4):243–249.
   PubMed Web of Science ®Google Scholar
• Conil JM, Georges B, De Lussy A, et al. Ciprofloxacin use in critically ill patients: pharmacokinetic and pharmacodynamic approaches. Int J Antimicrob Agents. 2008 Dec;32(6):505–510.
   PubMed Web of Science ®Google Scholar
• Li X, Zoller M, Fuhr U, et al. Ciprofloxacin in critically ill subjects: considering hepatic function, age, and sex to choose the optimal dose. J Antimicrob Chemother. 2019;74(3):682–690.
   PubMed Web of Science ®Google Scholar
• Malone RS, Fish DN, Abraham E, et al. Pharmacokinetics of levofloxacin and ciprofloxacin during continuous renal replacement therapy in critically ill patients. Antimicrob Agents Chemother. 2001 Oct;45(10):2949–2954.
   PubMed Web of Science ®Google Scholar
• Drusano GL, Weir M, Forrest A, et al. Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function. Antimicrob Agents Chemother. 1987 Jun;31(6):860–864.
   PubMed Web of Science ®Google Scholar
• Boelaert J, Valcke Y, Schurgers M, et al. The pharmacokinetics of ciprofloxacin in patients with impaired renal function. J Antimicrob Chemother. 1985 Jul;16(1):87–93.
   PubMed Web of Science ®Google Scholar
• Abdulla A, Rogouti O, Hunfeld NGM, et al. Population PKs and target attainment of ciprofloxacin in critically ill patients. European J Clin Pharmacology. 2020;76(7):957–967.
   PubMed Web of Science ®Google Scholar
• Chien SC, Rogge MC, Gisclon LG, et al. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Antimicrob Agents Chemother. 1997 Oct;41(10):2256–2260.
   PubMed Web of Science ®Google Scholar
• Fish DN, Chow AT. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet. 1997 Feb;32(2):101–119.
   PubMed Web of Science ®Google Scholar
• Czock D, Hüsig-Linde C, Langhoff A, et al. Pharmacokinetics of moxifloxacin and levofloxacin in intensive care unit patients who have acute renal failure and undergo extended daily dialysis. Clin J Am Soc Nephrol. 2006 Nov;1(6):1263–1268.
   PubMed Web of Science ®Google Scholar
• Roger C, Roberts JA, Clinical Pharmacokinetics ML. Pharmacodynamics of Oxazolidinones. Clin Pharmacokinet. 2018 May;57(5):559–575.
   PubMed Web of Science ®Google Scholar
• Brier ME, Stalker DJ, Aronoff GR, et al. Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrob Agents Chemother. 2003 Sep;47(9):2775–2780.
   PubMed Web of Science ®Google Scholar
• Lewis SJ, Switaj LA, Mueller BA. Tedizolid adsorption and transmembrane clearance during in vitro continuous renal replacement therapy. Blood Purif. 2015;40(1):66–71.
   PubMed Web of Science ®Google Scholar
• Sorli L, Luque S, Grau S, et al. Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study. BMC Infect Dis. 2013;13(1):380.
   PubMed Web of Science ®Google Scholar
• Michalopoulos AS, Falagas ME. Colistin: recent data on pharmacodynamics properties and clinical efficacy in critically ill patients. Ann Intensive Care. 2011 Aug 2;1(1):30.
   PubMedGoogle Scholar
• Tsuji BT, Pogue JM, Zavascki AP, et al. International Consensus Guidelines for the Optimal Use of the Polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019 Jan;39(1):10–39.
   PubMed Web of Science ®Google Scholar
• Estes KS, Derendorf H. Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin. Eur J Med Res. 2010 Nov 30;15(12):533–543.
   PubMed Web of Science ®Google Scholar
• Dvorchik BH, Brazier D, DeBruin MF, et al. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother. 2003 Apr;47(4):1318–1323.
   PubMed Web of Science ®Google Scholar
• Chaves RL, Chakraborty A, Benziger D, et al. Clinical and pharmacokinetic considerations for the use of daptomycin in patients with Staphylococcus aureus bacteraemia and severe renal impairment. J Antimicrob Chemother. 2014 Jan;69(1):200–210.
   PubMed Web of Science ®Google Scholar
• Xu X, Khadzhynov D, Peters H, et al. Population pharmacokinetics of daptomycin in adult patients undergoing continuous renal replacement therapy. Br J Clin Pharmacol. 2017 Mar;83(3):498–509.
   PubMed Web of Science ®Google Scholar
• Xie F, Li S, Cheng Z. Population pharmacokinetics and dosing considerations of daptomycin in critically ill patients undergoing continuous renal replacement therapy. J Antimicrob Chemother. 2020 Jun 1;75(6):1559–1566.
   PubMed Web of Science ®Google Scholar
• Investigators RS. Renal replacement therapy for acute kidney injury in Australian and New Zealand intensive care units: a practice survey. Crit Care Resusc. 2008 Sep;10(3):225–230.
   PubMedGoogle Scholar
• Taccone FS, Laterre PF, Spapen H, et al. Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. Crit Care. 2010;14(2):R53.
   PubMed Web of Science ®Google Scholar
• Karaiskos I, Friberg LE, Pontikis K, et al. Colistin Population Pharmacokinetics after Application of a Loading Dose of 9 MU Colistin Methanesulfonate in Critically Ill Patients. Antimicrob Agents Chemother. 2015 Dec;59(12):7240–7248.
   PubMed Web of Science ®Google Scholar
• Cristallini S, Hites M, Kabtouri H, et al. New Regimen for Continuous Infusion of Vancomycin in Critically Ill Patients. Antimicrob Agents Chemother. 2016 Aug;60(8):4750–4756.
   PubMed Web of Science ®Google Scholar
• Sime FB, Roberts MS, Roberts JA. Optimization of dosing regimens and dosing in special populations. Clin Microbiol Infect. 2015 Oct;21(10):886–893.
   PubMed Web of Science ®Google Scholar
• Van Lent-evers NA, Mathot RA, Geus WP, et al. Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis. Ther Drug Monit. 1999;21(1):63–73.
   PubMed Web of Science ®Google Scholar
• Stickel F, Worni M, Pache I, et al. Optimizing ribavirin exposure by therapeutic drug monitoring improves treatment response in patients with chronic hepatitis C genotype 1. Am J Gastroenterol. 2013;108(7):1176–1178.
   PubMed Web of Science ®Google Scholar
• Park WB, Kim NH, Kim KH, et al. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clin Infect Dis. 2012;55(8):1080–1087.
   PubMed Web of Science ®Google Scholar
• Hagel S, Fiedler S, Hohn A, et al. Therapeutic drug monitoring-based optimisation of piperacillin/tazobactam to improve outcome in patients with sepsis (TARGET): a prospective, multi-centre, randomised controlled trial. Trials. 2019;20(1):330.
   PubMedGoogle Scholar
• Abdulla A, Ewoldt TM, Hunfeld NGM, et al. The effect of therapeutic drug monitoring of beta-lactam and fluoroquinolones on clinical outcome in critically ill patients: the DOLPHIN trial protocol of a multi-centre randomised controlled trial. BMC Infect Dis. 2020 Jan;20(1):57.
   PubMed Web of Science ®Google Scholar
• Rodriguez Colomo O, Alvrez Lerma F, Gonzalez Pérez MI, et al. Impact of administration of vancomycin or linezolid to critically ill patients with impaired function. Eur J Clin Microbiol Infect Dis. 2011 May;30(5):635–643.
   PubMed Web of Science ®Google Scholar
• Abhisekh SR, Haikal A, Hammoud KA, et al. Vancomycin and the Risk of AKI: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2016;11(12):2132–2140.
   PubMed Web of Science ®Google Scholar
• Ordooei JA, Shokouhi S, Sahraei Z. A review on colistin nephrotoxicity. Eur J Clin Pharmacol. 2015;71(7):801–810.
   PubMed Web of Science ®Google Scholar
• Wargo KA, Edwards JD. Aminoglycoside-induced nephrotoxicity. J Pharm Pract. 2014;27(6):573–577.
   PubMedGoogle Scholar